Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Recommendation of “Moderate Buy” by Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has been given a consensus recommendation of “Moderate Buy” by the fourteen analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $32.20.

Several analysts recently issued reports on DNLI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, January 21st. Wolfe Research started coverage on Denali Therapeutics in a research report on Monday, February 23rd. They issued a “peer perform” rating for the company. BTIG Research boosted their price target on Denali Therapeutics from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Morgan Stanley restated an “overweight” rating and set a $40.00 price objective on shares of Denali Therapeutics in a report on Thursday, January 8th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $40.00 price objective on shares of Denali Therapeutics in a report on Monday, March 2nd.

Insider Activity at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 17,218 shares of the firm’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the completion of the transaction, the insider directly owned 282,828 shares of the company’s stock, valued at $4,666,662. This trade represents a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ryan J. Watts sold 35,198 shares of the business’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $580,767.00. Following the transaction, the chief executive officer directly owned 296,833 shares of the company’s stock, valued at $4,897,744.50. The trade was a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 12.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. State of Wyoming grew its holdings in Denali Therapeutics by 24.7% in the 4th quarter. State of Wyoming now owns 2,686 shares of the company’s stock worth $44,000 after acquiring an additional 532 shares during the last quarter. Intrust Bank NA lifted its position in Denali Therapeutics by 5.6% during the 4th quarter. Intrust Bank NA now owns 11,164 shares of the company’s stock valued at $184,000 after acquiring an additional 589 shares during the period. ADAR1 Capital Management LLC lifted its position in Denali Therapeutics by 1.2% during the 4th quarter. ADAR1 Capital Management LLC now owns 52,116 shares of the company’s stock valued at $860,000 after acquiring an additional 600 shares during the period. Pier 88 Investment Partners LLC boosted its stake in Denali Therapeutics by 1.1% during the fourth quarter. Pier 88 Investment Partners LLC now owns 68,200 shares of the company’s stock worth $1,126,000 after acquiring an additional 760 shares in the last quarter. Finally, Tudor Investment Corp ET AL grew its holdings in Denali Therapeutics by 1.7% in the third quarter. Tudor Investment Corp ET AL now owns 56,368 shares of the company’s stock worth $818,000 after purchasing an additional 920 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Trading Up 0.7%

DNLI opened at $20.71 on Wednesday. The stock has a market capitalization of $3.28 billion, a P/E ratio of -6.97 and a beta of 1.02. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $23.77. The firm’s fifty day simple moving average is $20.03 and its 200 day simple moving average is $17.58.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.02. During the same period last year, the company posted ($0.67) earnings per share. As a group, research analysts anticipate that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.